LightDark Log in Sign up

‹ Back to screener

ERIS.NS Eris Lifesciences Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2026-02-20 ₹1342.40
2026-08-21 ₹1316.60
Change over window -1.92%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 69.0%
Trailing 20-day average 62.9%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 86138 59397 68.96%
2026-08-27 51939 32224 62.04%
2026-08-26 84947 56678 66.72%
2026-08-25 59489 32607 54.81%
2026-08-24 45974 26955 58.63%
2026-08-21 56997 30166 52.93%
2026-08-20 80602 48998 60.79%
2026-08-19 77295 45913 59.40%
2026-08-18 125273 94879 75.74%
2026-08-17 68808 38436 55.86%
2026-08-14 39198 23117 58.97%
2026-08-13 53868 28917 53.68%
2026-08-12 67924 44083 64.90%
2026-08-11 340882 274505 80.53%
2026-08-10 32355 20363 62.94%
2026-08-07 40491 26037 64.30%
2026-08-06 53999 32520 60.22%
2026-08-05 48727 31980 65.63%
2026-08-04 92040 65070 70.70%
2026-08-03 110236 66387 60.22%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers ERIS.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
18 Aug 2023 Sabyasachi Sharma Employees/Designated Employees Sell Market Sale 2000 1591492 0.01% XBRL
06 Feb 2023 Amit Indubhushan Bakshi Promoters Buy Market Purchase 11750 7226835 40.84% XBRL
23 Jan 2023 Amit Indubhushan Bakshi Director Buy Market Purchase 203000 127890000 40.82% XBRL
15 Dec 2022 Amit Indubhushan Bakshi Director Buy Market Purchase 396262 262721706 40.68% XBRL
08 Dec 2022 Amit Indubhushan Bakshi Promoters Buy Market Purchase 165000 109015828 40.39% XBRL
21 Sep 2022 Vijaya Sampath Other Sell Market Sale 3400 2366144 0.00% XBRL
23 Jun 2022 Sabyasachi Sharma - Buy ESOP 4990 2250689 0.01% XBRL
23 Jun 2022 Chetan Doshi - Buy ESOP 4943 2229490 0.00% XBRL
26 May 2022 Chetan Doshi - Sell Market Sale 2000 1417800 0.00% XBRL
23 May 2022 Sabyasachi Sharma - Sell Market Sale 3000 2139800 0.00% XBRL
15 Apr 2022 Chetan Doshi - Buy ESOP 4500 2029680 0.00% XBRL
25 Dec 2021 Chetan Doshi Employees/Designated Employees Sell Market Sale 1000 798950 0.00% XBRL
25 Dec 2021 Vijay Joshi Employees/Designated Employees Buy ESOP 5542 2499664 0.01% XBRL
25 Dec 2021 Chetan Doshi Employees/Designated Employees Buy ESOP 8000 3608320 0.01% XBRL
12 Nov 2021 Himanshu Jayantbhai Shah Promoters Sell Market Sale 10249 8399362 0.35% XBRL
08 Nov 2021 Himanshu Jayantbhai Shah Promoters Sell Market Sale 2130 1741557 0.36% XBRL
28 Sep 2021 Sachin Shah - Buy ESOP 9975 4499124 0.02% XBRL
28 Sep 2021 Vijay Joshi - Buy ESOP 5542 2499663 0.01% XBRL
28 Sep 2021 Chetan Doshi - Buy ESOP 2500 1127600 0.00% XBRL
14 Sep 2021 CHETAN DOSHI - Sell Market Sale 882 678258 0.00% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers ERIS.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹1328.20 INR (live) · fetched 2026-08-24 01:34 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
29.69
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹1,328.20 / (₹6,195,200,000 / 138,500,000 shares) = ₹1,328.20 / ₹44.73 EPS
FY2025-26 · Annual filing
ROE
15.87%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹6,195,200,000 / ₹39,026,700,000 = 15.87%
FY2025-26 · Annual filing
Debt/Equity
0.59
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹23,096,800,000 / ₹39,026,700,000 = 0.59
FY2025-26 · Annual filing
Current Ratio
0.74
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹15,398,500,000 / ₹20,771,000,000 = 0.74
FY2025-26 · Annual filing
ROCE
13.66%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹8,483,600,000 / (₹39,026,700,000 + ₹23,096,800,000) = 13.66%
FY2025-26 · Annual filing
Dividend Yield
0.00%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹0 / 138,500,000 shares) / ₹1,328.20 = ₹0.00 / ₹1,328.20
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 22.9%
Net Profit (3y) 17.5%
Revenue (5y, 3.0y actual) 22.9%
Net Profit (5y) 17.5%
Revenue (10y, 3.0y actual) 22.9%
Net Profit (10y) 17.5%

Operating Margin Trend

Expanding

FY2022-23 25.6%
FY2023-24 25.7%
FY2024-25 24.9%
FY2025-26 27.1%

ROCE Trajectory

FY2022-23 14.1%
FY2023-24 8.7%
FY2024-25 12.5%
FY2025-26 13.7%

Earnings Quality

No persistent gap detected

Net Profit CAGR 17.47% vs CFO CAGR 22.62% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit +76.08% vs CFO -49.48%

Sector-Relative Percentile (Healthcare)

ROE 59th
ROCE 28th
Debt/Equity 11th
P/E 83th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹550.92 Cr. ₹719.72 Cr. ₹738.95 Cr. ₹727.45 Cr. ₹705.30 Cr. ₹773.00 Cr. ₹792.41 Cr. ₹807.45 Cr. ₹756.56 Cr. ₹873.25 Cr. RevenueFromOperations
Net Profit ₹70.96 Cr. incl. minority ₹79.63 Cr. ₹83.18 Cr. incl. minority ₹89.42 Cr. ₹91.59 Cr. incl. minority ₹96.35 Cr. ₹83.62 Cr. incl. minority ₹86.93 Cr. ₹93.84 Cr. incl. minority ₹102.35 Cr. ₹117.99 Cr. incl. minority ₹125.10 Cr. ₹120.19 Cr. incl. minority ₹134.47 Cr. ₹99.72 Cr. incl. minority ₹108.83 Cr. ₹281.61 Cr. incl. minority ₹279.10 Cr. ₹142.45 Cr. incl. minority ₹143.32 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers ERIS.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent6195200000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital138500000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets15398500000.0
CurrentLiabilities20771000000.0
EquityAttributableToOwnersOfParent39026700000.0
BorrowingsCurrent + BorrowingsNoncurrent23096800000.0

My notes